Reports Q3 revenue $478.9M, consensus $498.85M. Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, “Our performance for the third quarter was within our guidance range communicated last quarter. That said, our healthcare business is navigating a clear transition away from COVID-era conditions. We are beginning to see that customer behavior and sensor purchasing patterns are shifting back to the pre-pandemic growth trend line we saw from 2017 to 2019. Together with our record contracting performance through the third quarter, this reinforces our conviction in the underlying long-term growth rate for our healthcare business. As we emerge from this transition year, these trends, along with our new product launches and rapid growth in our hearables category, are setting the stage for a strong 2024.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MASI:
- Masimo options imply 13.5% move in share price post-earnings
- Masimo gets ‘significant win’ over Apple in patent case, says BTIG
- Masimo up 8% to $87 after ITC patent ruling on Apple Watches
- Will Apple’s (NASDAQ:AAPL) Watch Sales Come Under Pressure?
- Masimo confirms ITC’s exclusion order for infringing Apple Watches on its patent